Entrada Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Entrada Therapeutics, Inc. (TRDA) on April 4, 2023. The report discloses corporate governance changes effective as of the filing date. The Company is an emerging growth company incorporated in Delaware.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on board appointments and director compensation arrangements.
Material Changes
- Board Expansion: The Board of Directors expanded from seven to eight members.
- New Appointment: Bernhardt Zeiher, M.D., was appointed as a Class II director, serving until the 2023 annual meeting of stockholders.
- Committee Assignment: Dr. Zeiher was appointed to the Nominating and Corporate Governance Committee. The Audit and Compensation Committees remain unchanged.
Compensation and Governance Details
Dr. Zeiher's compensatory arrangements include:
- Initial Stock Option: Granted an option to purchase 32,000 shares of common stock, vesting in equal monthly installments over three years.
- Cash Fees: An annual director fee of $40,000 and an annual committee fee of $4,000 for the Nominating and Corporate Governance Committee.
- Future Grants: Eligible for annual stock option grants starting in 2024, valued at the lesser of $250,000 or an option to purchase 16,000 shares, vesting in full upon the first anniversary or the next annual meeting.
The filing confirms no family relationships or undisclosed related person transactions exist between Dr. Zeiher and other directors or officers.
Key Facts for Investor Verification
- Verify the impact of the new board member on the Company's strategic direction and governance structure.
- Review the attached press release (Exhibit 99.1) for additional context on Dr. Zeiher's background.
- Monitor future filings for the vesting schedule of the initial 32,000 share option grant.
- Note that this filing contains no financial performance data; refer to the most recent 10-Q or 10-K for financial metrics.